Thanks FinFree, unfortunately I only got to sit in on the first...

Thanks FinFree, unfortunately I only got to sit in on the first few minutes of the LDX conference call of the results presentation as it was scheduled at the same time as NXS and NXS had some juicy legal proceedings updates I wanted to hear the CEO provide an update on

I guess we'll have to 'watch this space' on the FDA approval and the level of demand for FebriDx post 510(k) approval. I could be greatly over anticipating its uptake in the US market, and the current manufacturing capacity of AT1 could be entirely appropriate for the number of devices LDX will need.